

HCERES

High Council for the Evaluation of Research
and Higher Education

Department of Research Evaluation

report on research unit:

Institut de Neurophysiopathologie

INP

under the supervision of
the following institutions
and research bodies:

Aix-Marseille Université

Centre National de la Recherche Scientifique – CNRS

HCERES

High Council for the Evaluation of Research
and Higher Education

Department of Research Evaluation

In the name of HCERES,¹

Michel Cosnard, president

In the name of the experts committee,²

Myriam Bernaudin, chairwoman of the
committee

Under the decree No.2014-1365 dated 14 november 2014,

¹ The president of HCERES "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5)

² The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2)

Evaluation report

This report is the sole result of evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

| | |
|-------------------------------------|-----------------------------------|
| Unit name: | Institut de Neurophysiopathologie |
| Unit acronym: | INP |
| Label requested: | UMR |
| Current number: | 7259 |
| Name of Director (2016-2017): | Mr Michel KRESTCHATISKY |
| Name of Project Leader (2018-2022): | Mr Michel KRESTCHATISKY |

Expert committee members

| | |
|---|---|
| Chair: | Ms Myriam BERNAUDIN, Université de Caen |
| Experts: | Mr Emmanuel BROUILLET, Université Paris-Sud, Paris-Saclay (representative of the CoNRS) Mr Alain BUISSON, Université Grenoble Alpes Mr Pascal EZAN, Université Paris 5 (representative of supporting personnel) Mr Jean-Philippe HUGNOT, Université de Montpellier Ms Brigitte MALGRANGE, Université de Liège, GIGA-Neurosciences, Belgium Ms Claire RAMPON, Université de Toulouse 3 Mr Cédric RAOUL, Université de Montpellier Ms Rachel SHERRARD, Université Pierre et Marie Curie, Paris 6 (representative of the CNU) |
| Scientific delegate representing the HCERES: | Mr Christian GIAUME |
| Representatives of supervising institutions and bodies: | Mr Pierre CHIAPPETTA, Aix-Marseille Université Mr Bernard POULAIN, CNRS |
| Head of Doctoral School: | Mr Jean-Louis MÈGE, ED n° 62, “Sciences de la Vie et de la Santé” |

1 • Introduction

History and geographical location of the unit

The INP project is a multi-team project proposing to regroup around 130 people in eleven teams from three existing units (UMR7259, UMR7286, UMR_S911). Seven teams are already existing (4) or emerged (3) from the NICN-UMR7259 laboratory headed by Mr Michel KRESTCHATISKY and affiliated with the CNRS and AMU (created *ex nihilo* in 2002 as a FRE2533, and then became UMR6184 for the 2004-2007 period and UMR7259 for the 2012-2017 period; three teams originated from the CRO2-UMR_S911 laboratory, headed by Mr Dominique LOMBARDO and affiliated with Inserm and AMU and one team is an ATIP team hosted presently in the CRN2M-UMR7286 laboratory, headed by Mr Alain ENJALBERT and affiliated with the CNRS and AMU. One of these eleven teams, VECT-HORUS, is a spin-off of the NICN leading to the creation project of a Laboratoire Commun de Recherche, LCR (Joint Research Laboratory).

As part as the “Neuro-Timone opération” (CPER funding of 18,5M€), the teams presently located at the site Nord of the Medical Faculty or the Medical and Pharmacy Faculties of the Timone Campus will be regrouped in the Medical Faculty at the Timone campus by creating a new laboratory dedicated to the study of Central Nervous System (CNS) diseases and the development of therapeutic strategies.

Management team

The institute will be headed by Mr Michel KRESTCHATISKY.

HCERES nomenclature

Principal: SVE4 Neurologie.

Secondary:

- SVE5 Physiologie, Physiopathologie, Cardiologie, Pharmacologie, Endocrinologie, Cancer, Technologies Médicales;
- SVE2 Biologie Cellulaire, Imagerie, Biologie Moléculaire, Biochimie, Génomique, Biologie Systémique, Développement, Biologie Structurale;
- SVE6 Santé Publique, Epidémiologie, Recherche Clinique.

Scientific domains

The project is focused on neuroinflammatory and neurodegenerative processes, tumorigenesis (neuro-oncology), neurocytoskeleton, and modification of the blood-brain barrier (BBB) in different pathological conditions including Alzheimer disease, multiple sclerosis, autism and glioma with molecular, cellular and animal models, cellular imaging, chemistry as well as clinical approaches.

Unit workforce

| Unit workforce | Number on 30/06/2016 | Number on 01/01/2018 |
|--|----------------------|----------------------|
| N1: Permanent professors and similar positions | 5 | 10 |
| N2: Permanent researchers from Institutions and similar positions | 10 | 28 |
| N3: Other permanent staff (technicians and administrative personnel) | 9 | 39 |
| N4: Other researchers (Postdoctoral students, visitors, etc.) | 5 | |
| N5: Emeritus | 1 | |
| N6: Other contractual staff (technicians and administrative personnel) | 1 | |
| N7: PhD students | 10 | |
| TOTAL N1 to N7 | 41 | |
| Qualified research supervisors (HDR) or similar positions | 13 | |

| Unit record | From 01/01/2011 to 30/06/2016 |
|---|-------------------------------|
| PhD theses defended | 8 |
| Postdoctoral scientists having spent at least 12 months in the unit | 10 |
| Number of Research Supervisor Qualifications (HDR) obtained during the period | 0 |

2 • Assessment of the unit

Global assessment of the unit

The INP project is focused on the understanding of the pathophysiological processes in diseases and disorders of the central nervous system (CNS). Collaborative efforts will be centered on neuroinflammatory and neurodegenerative processes, tumorigenesis (neuro-oncology) and alteration/modification of the blood-brain-barrier (BBB) in different pathological conditions including Alzheimer disease, multiple sclerosis, autism and glioma. The development of new diagnostics and therapeutics, based in particular on cellular (stem cell/inducible-Pluripotent Stem Cell, iPSC) and molecular (vectors targeting drugs to the CNS) strategies, is also a main objective of the unit project. INP will address these objectives with complementary basic and applied approaches from molecular, cellular and animal models to translational approaches thanks to a strong partnership with pharmaceutical industries and interactions with clinical teams of the regional and other medical institutions. Indeed, current restructuring to include 3 teams from the CRO2 unit (from the UMR_S911 Center for Research in Oncobiology and Oncopharmacology), and the recruitment of a young CNRS researcher allows the INP project to expand its research domain of cellular therapy (iPSC) and to broaden its application to include neuro-oncology.

INP will include around 130 persons with 35 permanent researchers including 10 full-time researchers (7 CNRS and 3 Inserm) and 28 professors, assistant professors or PH (AMU, AP-HM). The INP project will benefit of a strong technicians/engineers/administrative support with 39 permanent technicians/engineers/administrative staff (28 AMU, 9 CNRS, 2 INSERM) with 12 involved in common services of the unit. Moreover, 33 non-permanent staff is already identified for the start of the contract (2018) with 10 post-docs; 17 PhD and other students.

Overall, the unit has an excellent and original scientific activity, which is competitive regarding the national and international community.

Moreover, the creation of a start-up company by the NICN laboratory, VECT-HORUS, more than 10 years ago represents a unique platform in Europe for the vector molecules development to facilitate drug delivery into the brain and allowing transfer and exploitation of the unit researches. The unit activity at the social, economic and cultural environment is outstanding.

Thanks to the “NeuroTimone Opération”, all the INP teams and members will be hosted in a unique site and fully renovated laboratory that therefore answers to a weak point mentioned in the previous report. In addition, this operation will allow the INP to be located on the same site as two other neuroscience institutes (INT and INS) that will favour the creation of conjoint platforms (animal care facility, cellular imaging platform, etc.) and reinforce the visibility, already well achieved, of the Timone site in neurosciences and the future INP unit in a several research areas: Alzheimer disease, BBB vectorisation, cell therapy, neurodegeneration and glioma. The achievement of the excellent scientific projects of the unit will strongly depend on the ability of all the unit members to be regrouped, in a short time, in this unique NeuroTimone site.

The unit has a very good involvement in training through research in particular at the PhD level.

The project of creation of the INP has been strongly/dynamically conducted by the future director, in a collegial and federative manner. As a consequence, all members of the INP are very enthusiastic not only by their physical regrouping on a single site but also by new scientific projects that emerge from their discussions. Strong transversal axes, which encompass several different research teams, have already been identified on neurodegeneration, neuroinflammation, cytoskeleton and neuro-oncology.